Why FDA Compliance Is Now a Market Entry Strategy for Global Manufacturers

The United States remains the largest single consumer market in the world, and for foreign manufacturers, gaining access to it is increasingly a question of regulatory readiness rather than product quality alone. Companies that move decisively on FDA compliance are shortening their path to market. Those that treat it as an afterthought are discovering that the FDA’s enforcement infrastructure has become sophisticated enough to identify and act on non-compliance faster than ever before.

For business leaders overseeing international expansion, understanding how FDA registration and U.S. agent requirements work is no longer a task to delegate entirely to a compliance team and forget about. It is a strategic input with direct consequences for revenue, market timing, and supply chain continuity.

The Scale of the Requirement

The FDA regulates approximately 78 percent of the U.S. food supply and oversees a product portfolio that includes pharmaceuticals, medical devices, cosmetics, dietary supplements, and radiation-emitting devices. Foreign facilities that manufacture, process, pack, or hold any of these products for U.S. consumption are subject to mandatory registration requirements under the Federal Food, Drug, and Cosmetic Act.

Registration is not a one-time filing. Food facility registrations must be renewed biennially during the October 1 to December 31 window in even-numbered years. Medical device and drug establishment registrations renew annually during the same window. Missing a renewal deadline does not simply result in a lapse on paper. It can trigger an import refusal at the U.S. border, meaning shipments that have already been produced and transported are turned away at the point of entry.

For a foreign manufacturer shipping into the United States for the first time, or a company scaling up its U.S. distribution, this is not a theoretical risk. The FDA’s Operational and Administrative System for Import Support (OASIS) flags non-registered facilities at the port level, and import refusals are a matter of public record.

The U.S. Agent Requirement and What It Actually Means

Every foreign facility required to register with the FDA must also designate a U.S. Agent. This requirement, codified under 21 CFR Part 207 for drug establishments and parallel provisions for food, device, and cosmetic companies, mandates that the designated agent be physically located in the United States, available by phone during regular business hours, and capable of receiving and relaying official FDA communications.

The U.S. agent is not simply an administrative formality. They are the FDA’s primary communication channel to the foreign facility. If the FDA has a compliance question, schedules an inspection, issues a warning, or needs to transmit documents, that communication runs through the U.S. agent first. A foreign facility that designates an unresponsive or unqualified agent is effectively creating a communication breakdown with a federal regulator, which carries its own set of risks.

The strategic implication for business leaders is straightforward: the quality of the U.S. agent appointment is a direct variable in how efficiently a company can respond to FDA inquiries, resolve compliance issues, and maintain uninterrupted market access. Choosing a qualified, experienced U.S. agent is not a cost to minimize. It is a risk management decision.

The MoCRA Effect on the Cosmetics Industry

One of the most significant recent shifts in FDA compliance requirements came with the Modernization of Cosmetics Regulation Act of 2022, commonly referred to as MoCRA. For the first time, cosmetic manufacturers are now subject to mandatory FDA facility registration and product listing requirements. This represents a structural change in how the cosmetics industry operates in the United States.

Foreign cosmetic manufacturers selling into the U.S. market must register their facilities and list their products with the FDA. They must also designate a U.S. agent. Small businesses meeting certain revenue thresholds may qualify for an exemption, but the threshold criteria require careful evaluation. Companies that assumed their cosmetics products were outside FDA jurisdiction are now discovering otherwise, and the compliance window for many is already behind them.

According to the FDA’s own implementation guidance, failure to comply with MoCRA registration requirements can result in enforcement action, product detention, and import refusal. For cosmetics brands that have built U.S. distribution relationships with major retailers, a compliance gap at the FDA level creates downstream exposure with those retail partners as well.

Why Foreign Marketplace Sellers Face Particular Exposure

One group of foreign manufacturers that has been slower to engage with FDA compliance requirements is the growing population of international sellers operating on U.S. e-commerce platforms. Selling FDA-regulated products on Amazon or Walmart’s U.S. marketplace does not exempt a foreign company from registration requirements. A food product, dietary supplement, cosmetic, or medical device sold through an online marketplace is subject to the same regulatory framework as a product distributed through traditional retail channels.

What makes this a pressing business issue rather than simply a regulatory one is that marketplace platforms are themselves increasing their documentation and compliance requirements for third-party sellers. Amazon has periodically removed listings or suspended accounts for sellers unable to demonstrate regulatory compliance with FDA requirements. A foreign manufacturer investing in U.S. marketplace distribution without the corresponding FDA registration infrastructure is building on an unstable foundation.

The Foreign Supplier Verification Program (FSVP), established under the Food Safety Modernization Act, adds another layer. U.S. importers of food products are required to verify that their foreign suppliers meet FDA safety standards. Foreign suppliers shipping food into the United States need to understand that their U.S. import partners have their own verification obligations, and that incomplete or inaccurate compliance documentation on the supplier side creates problems for the entire import relationship.

The Cost and Timing Reality

One reason FDA compliance is sometimes delayed by foreign manufacturers is a lack of clarity on what it actually costs and how long it takes. The FDA charges its own government fees for certain registrations. Drug establishment registration fees, for example, are set annually by the FDA and are publicly available. Medical device annual establishment fees vary by company size. Export certificates carry per-certificate government fees. These are separate from any professional service fees paid to a U.S. agent or registration service provider.

Companies that work with a qualified FDA agent and registration service typically find the process faster and less prone to the errors and delays that come with self-filing. According to a 2023 analysis published by the National Law Review, regulatory compliance failures in FDA-regulated industries most commonly stem from incomplete submissions, incorrect facility information, and missed renewal deadlines, all of which are addressable with proper professional support.

For companies that are new to U.S. market entry, the cost of getting FDA compliance right the first time is meaningfully lower than the cost of an import refusal, a warning letter, or a marketplace suspension.

What Business Leaders Should Be Asking

The companies navigating FDA compliance most effectively are those where leadership treats it as a market access question rather than a legal checkbox. The practical questions worth asking at the executive level include: Is our U.S. agent designation current and accurate? Are our registrations up to date and scheduled for renewal? Do we have the correct registrations in place for every product category we ship into the United States? Are our import partners clear on our FSVP documentation?

For foreign manufacturers serious about building durable U.S. market presence, professional FDA registration and U.S. agent services provide both the compliance foundation and the ongoing responsiveness that U.S. market access requires. The regulatory environment is not getting simpler. The companies that treat compliance infrastructure as a competitive asset rather than a cost center will be better positioned to move quickly when market opportunities arise and to maintain continuity when the FDA comes knocking.